Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SARL SPFPL MLMVY PHARMA : revenue, balance sheet and financial ratios

SARL SPFPL MLMVY PHARMA is a French company founded 4 years ago, specialized in the sector Activités des sociétés holding. Based in LE BOULLAY-THIERRY (28210), this company of category PME shows in 2023 a net income positive of 40 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SARL SPFPL MLMVY PHARMA (SIREN 905163309)
Indicator 2023 2022
Revenue N/C N/C
Net income 40 317 € -6 441 €
EBITDA -4 070 € -1 929 €
Net margin N/C N/C

Revenue and income statement

In 2023, SARL SPFPL MLMVY PHARMA generates positive net income of 40 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

EBITDA (2023) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-4 070 €

EBIT (2023) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-4 070 €

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

40 317 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 665%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 86%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 7.4 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

664.778%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

86.498%

Repayment capacity (2023) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

7.415

Solvency indicators evolution
SARL SPFPL MLMVY PHARMA

Sector positioning

Debt ratio
664.78 2023
2022
2023
Q1: 0.03
Med: 10.87
Q3: 70.22
Average

In 2023, the debt ratio of SARL SPFPL MLMVY PHARMA (664.78) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
86.5% 2023
2022
2023
Q1: 17.2%
Med: 61.39%
Q3: 90.77%
Good

In 2023, the financial autonomy of SARL SPFPL MLMVY PHARMA (86.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
7.42 years 2023
2022
2023
Q1: 0.0 years
Med: 0.09 years
Q3: 3.23 years
Average +50 pts over 2 years

In 2023, the repayment capacity of SARL SPFPL MLMVY PHARMA (7.42) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 14.09. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

14.089

Interest coverage (2023) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-47.027

Liquidity indicators evolution
SARL SPFPL MLMVY PHARMA

Sector positioning

Liquidity ratio
14.09 2023
2022
2023
Q1: 126.86
Med: 619.0
Q3: 3548.33
Average

In 2023, the liquidity ratio of SARL SPFPL MLMVY PHARMA (14.09) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-47.03x 2023
2022
2023
Q1: -65.31x
Med: 0.0x
Q3: 0.0x
Average +7 pts over 2 years

In 2023, the interest coverage of SARL SPFPL MLMVY PHARMA (-47.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 119 days. Excellent situation: suppliers finance 119 days of the operating cycle (retail model).

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

119 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SARL SPFPL MLMVY PHARMA

Positioning of SARL SPFPL MLMVY PHARMA in its sector

Comparison with sector Activités des sociétés holding

Valuation estimate

Based on 63 transactions of similar company sales in 2023, the value of SARL SPFPL MLMVY PHARMA is estimated at 376 069 € (range 68 555€ - 558 055€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2023
63 tx
68k€ 376k€ 558k€
376 069 € Range: 68 555€ - 558 055€
NAF 5 année 2023

Valuation method used

Net Income Multiple
40 317 € × 9.3x = 376 070 €
Range: 68 555€ - 558 055€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 63 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des sociétés holding)

Compare SARL SPFPL MLMVY PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des sociétés holding

Frequently asked questions about SARL SPFPL MLMVY PHARMA

What is the revenue of SARL SPFPL MLMVY PHARMA ?

The revenue of SARL SPFPL MLMVY PHARMA is not publicly disclosed (confidential accounts filed with INPI).

Is SARL SPFPL MLMVY PHARMA profitable?

Yes, SARL SPFPL MLMVY PHARMA generated a net profit of 40 k€ in 2023.

Where is the headquarters of SARL SPFPL MLMVY PHARMA ?

The headquarters of SARL SPFPL MLMVY PHARMA is located in LE BOULLAY-THIERRY (28210), in the department Eure-et-Loir.

Where to find the tax return of SARL SPFPL MLMVY PHARMA ?

The tax return of SARL SPFPL MLMVY PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SARL SPFPL MLMVY PHARMA operate?

SARL SPFPL MLMVY PHARMA operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.